Comparative Pharmacology
Head-to-head clinical analysis: PYQUVI versus RASUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYQUVI versus RASUVO.
PYQUVI vs RASUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyquvi (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-2α, promoting erythropoietin production and iron mobilization, thereby stimulating erythropoiesis.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
400 mg orally once daily with food, continued until disease progression or unacceptable toxicity.
Subcutaneous injection: 200 mg once weekly.
None Documented
None Documented
The terminal elimination half-life is approximately 50 hours (range 40–60 hours), supporting once-daily dosing. Steady-state is achieved within 2–3 weeks of continuous dosing.
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Primarily hepatic metabolism via CYP3A4 and UGT1A9, with less than 5% of the dose excreted unchanged in urine. Fecal excretion accounts for approximately 70% of total clearance, primarily as metabolites.
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Category C
Category C
Antimetabolite
Antimetabolite